Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;1(8):evidctw2200018.
doi: 10.1056/EVIDctw2200018. eCollection 2022 Aug.

Improving clinical trial interpretation with ACCEPT analyses

Michelle N Clements  1 , Ian R White  1 , Andrew J Copas  1 , Victoria Cornelius  2 , Suzie Cro  2 , David T Dunn  2 , Matteo Quartagno  1 , Rebecca M Turner  1 , Conor D Tweed  1 , A Sarah Walker  1
Affiliations

Improving clinical trial interpretation with ACCEPT analyses

Michelle N Clements et al. NEJM Evid. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Acceptability Curve Estimation using Probability Above Threshold (ACCEPT) curves and tables for EARNEST and SECOND-LINE trials. An acceptability value is the probability that the true treatment difference is at least the acceptability threshold. Positive values indicate raltegravir is better than NRTI. For example, the probability that the true difference between treatments was at least 0 (i.e. that raltegravir is better than NRTI) was 89% in EARNEST and 70% in SECOND-LINE. Median estimates, 95% credible intervals from models, and pre-specified unacceptable differences are marked.
See this image and copyright information in PMC

References

    1. Amrhein V, Greenland S, McShane B. Nature Publishing Group; 2019. Scientists rise up against statistical significance. - PubMed
    1. Harrington D, D’Agostino Sr RB, Gatsonis C, et al. Mass Medical Soc; 2019. New guidelines for statistical reporting in the journal. - PubMed
    1. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. New England journal of medicine. 2014;371(3):234–47. - PubMed
    1. Second-Line Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. The Lancet. 2013;381(9883):2091–99. - PubMed
    1. Dunn DT, Copas AJ, Brocklehurst P. Superiority and non-inferiority: two sides of the same coin? Trials. 2018;19(1):499. - PMC - PubMed